Bioequivalence Study of Antihyperlipidemic in Human Volunteers

Bioequivalence study of Antihyperlipidemic drug Finofibrate in healthy human volunteers

ISBN: 978-3-659-28979-8
Verlag: LAP Lambert Academic Publishing

Buch, Englisch, 100 Seiten, Format (B × H): 150 mm x 220 mm

Finofibrate is an oral antihyperlipemic agent. In this investigation, we report randomized, single dose, open-label, three-treatment, three-period, three-sequence, crossover Clinical study in healthy 18 adult male human volunteers evaluating the bioequivalence of two new investigational formulation of Finofibrate 145 mg Tablets (manufactured by manufactured by Wockhardt Limited, India) and reference formulation Finofibrate ® 145 mg Tablet (® indicates reference formulation). In this investigation, we report randomized, single dose, open-label, three-treatment, three period, three-sequence, crossover Clinical study evaluating the bioequivalence of two new investigational formulation of Finofibrate 145 mg Tablets (manufactured by manufactured by Wockhardt Limited, India) and reference formulation Finofibrate ® 145 mg Tablet (® indicates reference formulation). Pharmacokinetic parameters were investigated and statistical analysis was done.

Autoren/Hrsg.

Wagh, Nilesh

Bhople, Amit

Thakre, Anup

Über Autor(innen)

Mr. Nilesh Wagh has obtained his Post graduation i.e. Master in Pharmacy with specialization in Pharmacology. In current he is perusing doctorate in Philosophy (PhD.) at University Department of Pharmaceutical Sciences, Nagpur University, India. His main area of research is bioavailability and bioequivalence study in human volunteers.